Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). InnoCare Pharma's share price for the quarter that ended in Sep. 2023 was HK$5.95. InnoCare Pharma's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 1,764.3 Mil. Therefore, InnoCare Pharma's market cap for the quarter that ended in Sep. 2023 was HK$10,497.7 Mil.
InnoCare Pharma's quarterly market cap
declined
from Dec. 2022 (HK$24,065.3 Mil) to Jun. 2023 (HK$12,456.1 Mil) and
declined
from Jun. 2023 (HK$12,456.1 Mil) to Sep. 2023 (HK$10,497.7 Mil).
InnoCare Pharma's annual market cap
increased
from Dec. 2020 (HK$17,584.3 Mil) to Dec. 2021 (HK$22,945.0 Mil) and
increased
from Dec. 2021 (HK$22,945.0 Mil) to Dec. 2022 (HK$24,065.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. InnoCare Pharma's Enterprise Value for Today is HK$1,608.0 Mil.
InnoCare Pharma Market Cap Historical Data
The historical data trend for InnoCare Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of InnoCare Pharma's Market Cap
For the Biotechnology subindustry, InnoCare Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's Market Cap falls into.
InnoCare Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
InnoCare Pharma's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (HKSE:09969) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
InnoCare Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of InnoCare Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09969 has been successfully added to your 